Cargando…

Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma

BACKGROUND: Anaplastic thyroid cancer (ATC) is considered the most lethal thyroid cancer, with an overall 5‐year survival rate below 10%. The FDA approved a BRAF/MEK inhibitor combination for the treatment of patients with BRAF‐mutated ATC. However, effective therapeutic options for patients with wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shuwen, Ji, Dongmei, Xue, Fen, Chen, Tongzhen, Wang, Yu, Ji, Qinhai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875607/ https://www.ncbi.nlm.nih.gov/pubmed/36535914 http://dx.doi.org/10.1002/cnr2.1770

Ejemplares similares

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
por: Xia, Lingfang, et al.
Publicado: (2022)

Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage IVB and C anaplastic thyroid cancer
por: Maurer, Elisabeth, et al.
Publicado: (2023)

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
por: Qu, Yuan-Yuan, et al.
Publicado: (2022)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
por: Ding, Xi, et al.
Publicado: (2023)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
por: Chen, Li, et al.
Publicado: (2022)

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
por: Xia, Lingfang, et al.
Publicado: (2022)

Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022)

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2022)

Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
por: Ge, Sai, et al.
Publicado: (2016)

Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report
por: Damásio, Inês, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
por: Qiao, Yujin, et al.
Publicado: (2022)

TIPS-13 A PHASE II STUDY OF NEOADJUVANT CAMRELIZUMAB AND APATINIB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS
por: Guo, Chengcheng, et al.
Publicado: (2023)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Anaplastic Thyroid Carcinoma
por: Taccaliti, Augusto, et al.
Publicado: (2012)

Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report
por: Wu, Jing, et al.
Publicado: (2022)

Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC
por: Ma, Ben, et al.
Publicado: (2018)

Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy
por: Xu, Liwei, et al.
Publicado: (2022)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
por: Ju, Wu-tong, et al.
Publicado: (2022)

Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
por: Huang, Dongmei, et al.
Publicado: (2022)

Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
por: Chen, Qiuyan, et al.
Publicado: (2018)

The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Anaplastic Thyroid Carcinoma: An Update
por: Jannin, Arnaud, et al.
Publicado: (2022)

Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
por: Zhou, Rui-Qin, et al.
Publicado: (2023)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
por: Su, Xi, et al.
Publicado: (2020)

A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
por: Huang, Julu, et al.
Publicado: (2023)

Subtotal Resection of an Anaplastic Ganglioglioma in Pregnancy
por: Bicocca, Matthew J., et al.
Publicado: (2018)

The Complete Surgical Resection Without the Radiotherapy for a Recurred Anaplastic Ependymoma at the Cervicomedullary Junction
por: Lee, Chang Sun, et al.
Publicado: (2012)

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
por: Yang, Peng, et al.
Publicado: (2021)

Risk Factors for Anaplastic Thyroid Cancer
por: Zivaljevic, V., et al.
Publicado: (2014)

The Role of Tracheostomy in Anaplastic Thyroid Carcinoma
por: Xu, Jia, et al.
Publicado: (2015)

Anaplastic Thyroid Carcinoma with Gastric Metastasis
por: CHAVEZ, A.A.L., et al.
Publicado: (2018)

Treatment Outcomes in Anaplastic Thyroid Cancer
por: Corrigan, Kelsey L., et al.
Publicado: (2019)

Anaplastic Cancer of the Thyroid: The Viper in the Pit
por: Seshadri, Krishna G.
Publicado: (2019)

Genetic Alterations in Anaplastic Thyroid Carcinoma
por: Rashid, M., et al.
Publicado: (2019)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e7vpirkrksos1n472eu399j85q